Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Aclaris Therapeutics Inc(ACRS)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for ACRS
09/25/2026: ACRS (2-star) is currently NOT-A-BUY. Pass it for now.
Aclaris Therapeutics is a clinical-stage biotechnology company focused on developing small molecule kinase inhibitors to treat immuno-inflammatory diseases. Its strength lies in a specialized R&D platform aimed at high-need medical markets. The primary investment story rests on the successful clinical progression and potential future licensing of its drug candidates, such as ATI-1777. However, the company faces significant risks, including the lack of current commercial revenue, clinical trial execution uncertainty, and intense competition from much larger, well-funded pharmaceutical firms. This stock is best suited for risk-tolerant investors who monitor clinical trial readouts and potential partnership developments as primary indicators of long-term value creation.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | This is a high-risk growth play that requires success in clinical trials to generate significant upside. |
| Momentum investor | Strong fit while signal remains positive | Momentum traders may engage during periods of positive clinical news flow or trial data announcements. |
| Value investor | Weak fit | The company lacks current earnings or consistent cash flow, making traditional value metrics inapplicable. |
| Dividend investor | Weak fit | The company does not pay dividends and likely will not for the foreseeable future. |
| Low-risk investor | Weak fit | The high volatility and clinical trial risks are unsuitable for risk-averse portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical trial results can cause massive, sudden swings in stock price. |
| Valuation risk | High | Valuations are highly speculative based on future potential rather than current financial performance. |
| Competition risk (Immunology) | High | The company must outperform larger rivals with more resources and established market positions. |
| Business quality | Medium | The company is in the development phase, lacking the operational durability of mature firms. |
| Dividend income | Low / none | No income is generated for investors through dividends. |
| Execution risk | High | Success depends entirely on the outcome of complex, multi-year clinical trials. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit 53.57% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 791.93M USD | Price to earnings Ratio - | 1Y Target Price 10.18 |
Price to earnings Ratio - | 1Y Target Price 10.18 | ||
Volume (30-day avg) 2.3M shares | Beta 0.8 | 52 Weeks Range 1.74 - 6.60 | Updated Date 09/25/2026 |
52 Weeks Range 1.74 - 6.60 | Updated Date 09/25/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.58 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Drug Development | Clinical trial advancement of proprietary assets. | The company survives on potential future licensing or drug sale revenue. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE - | Forward PE - | Enterprise Value 681.97M | Price to Sales(TTM) 96.35 |
Enterprise Value 681.97M | Price to Sales(TTM) 96.35 | ||
Enterprise Value to Revenue 82.98 | Enterprise Value to EBITDA 0.28 | Shares Outstanding 147.20M | Shares Floating 101.17M |
Shares Outstanding 147.20M | Shares Floating 101.17M | ||
Percent Insiders 2.18 | Percent Institutions 84.01 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Aclaris Therapeutics Inc
Exchange NASDAQ | Headquarters Wayne, PA, United States | ||
IPO Launch date 2015-10-07 | Co-Founder, CEO & Chairman Dr. Neal S. Walker D.O., M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 69 | Website https://www.aclaristx.com |
Full time employees 69 | Website https://www.aclaristx.com | ||
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.